Geode Capital Management
SYRS

Geode Capital Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Geode Capital Management’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-196,252
Closed -$45.1K – 4526
2024
Q4 		$45.1K Sell
196,252
-8,443
-4% -$10.1K ﹤0.01% 4259
2024
Q3 		$440K Sell
204,695
-21,415
-9% -$76.9K ﹤0.01% 3633
2024
Q2 		$1.17M Buy
226,110
+5,865
+3% +$30.8K ﹤0.01% 3249
2024
Q1 		$1.18M Buy
220,245
+58,682
+36% +$406K ﹤0.01% 3303
2023
Q4 		$1.26M Buy
161,563
+23,698
+17% +$81.2K ﹤0.01% 3258
2023
Q3 		$545K Buy
137,865
+8,002
+6% +$29.9K ﹤0.01% 3568
2023
Q2 		$409K Buy
129,863
+46,784
+56% +$150K ﹤0.01% 3726
2023
Q1 		$222K Buy
83,079
+12,563
+18% +$48.7K ﹤0.01% 3996
2022
Q4 		$253K Buy
70,516
+101
+0.1% +$438 ﹤0.01% 3967
2022
Q3 		$453K Buy
70,415
+22,044
+46% +$179K ﹤0.01% 3772
2022
Q2 		$465K Sell
48,371
-50,152
-51% -$469K ﹤0.01% 3809
2022
Q1 		$1.17M Buy
98,523
+3,203
+3% +$57.3K ﹤0.01% 3537
2021
Q4 		$3.11M Buy
95,320
+9,555
+11% +$387K ﹤0.01% 3146
2021
Q3 		$3.83M Sell
85,765
-10,880
-11% -$531K ﹤0.01% 3066
2021
Q2 		$5.27M Buy
96,645
+13,344
+16% +$790K ﹤0.01% 2865
2021
Q1 		$6.23M Buy
83,301
+24,291
+41% +$2.52M ﹤0.01% 2673
2020
Q4 		$6.4M Buy
59,010
+939
+2% +$85.7K ﹤0.01% 2466
2020
Q3 		$5.13M Buy
58,071
+1,691
+3% +$192K ﹤0.01% 2383
2020
Q2 		$6.01M Buy
56,380
+6,561
+13% +$589K ﹤0.01% 2223
2020
Q1 		$2.95M Buy
49,819
+2,264
+5% +$154K ﹤0.01% 2451
2019
Q4 		$3.29M Buy
47,555
+2,412
+5% +$146K ﹤0.01% 2710
2019
Q3 		$4.68M Buy
45,143
+551
+1% +$52K ﹤0.01% 2418
2019
Q2 		$4.13M Buy
44,592
+15,539
+53% +$1.08M ﹤0.01% 2513
2019
Q1 		$2.65M Buy
29,053
+4,086
+16% +$285K ﹤0.01% 2687
2018
Q4 		$1.39M Buy
24,967
+2,324
+10% +$177K ﹤0.01% 2961
2018
Q3 		$2.7M Buy
22,643
+1,149
+5% +$133K ﹤0.01% 2723
2018
Q2 		$2.19M Buy
21,494
+5,137
+31% +$636K ﹤0.01% 2802
2018
Q1 		$2.12M Buy
16,357
+6,781
+71% +$741K ﹤0.01% 2724
2017
Q4 		$931K Buy
9,576
+87
+0.9% +$11.7K ﹤0.01% 3131
2017
Q3 		$1.4M Buy
9,489
+1,107
+13% +$208K ﹤0.01% 2962
2017
Q2 		$1.35M Buy
8,382
+4,376
+109% +$687K ﹤0.01% 2955
2017
Q1 		$638K Buy
4,006
+422
+12% +$51.5K ﹤0.01% 3217
2016
Q4 		$435K Buy
3,584
+109
+3% +$15.3K ﹤0.01% 3315
2016
Q3 		$481K Buy
+3,475
New +$441K ﹤0.01% 3264

Other funds holding SYRS

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
1CM
1492 Capital Management Milwaukee, Wisconsin $339M AUM 120.53% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Geode Capital Management's SYRS Position: Q1 2025 in Review

Geode Capital Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2025, closing a stake of 196,252 shares — an estimated $45.1K sold.

Geode Capital Management first reported a position in SYRS in Q3 2016 and held it in 34 quarters. The position peaked at $6.4M in Q4 2020. 7 funds tracked by Wall St. Rank hold SYRS as of Q1 2025.

  • Geode Capital Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Geode Capital Management sold 196,252 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2025, an estimated $45.1K.
  • Geode Capital Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2016 and held it in 34 quarters.
  • Geode Capital Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $6.4M in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2025.

Based on Geode Capital Management's 13F filing for Q1 2025, filed 13 May 2025.